Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GTBP
stocks logo

GTBP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.630
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 0.630
sliders
Low
8.00
Averages
8.00
High
8.00
Roth Capital
Buy
downgrade
$11 -> $8
2025-11-17
Reason
Roth Capital
Price Target
$11 -> $8
2025-11-17
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on GT Biopharma to $8 from $11 and keeps a Buy rating on the shares. GT Biopharma closed Q3 with $2.6M in cash, sufficient to fund operations into 1Q26, the analyst tells investors in a research note. The company is advancing a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33+ hematologic malignancies, with initial data expected in 1Q26, and has resumed preclinical development of GTB-5550 for B7H3+ solid tumors, targeting an IND submission by YE25/1Q26.
See All Ratings

Valuation Metrics

The current forward P/E ratio for GT Biopharma Inc (GTBP.O) is -0.67, compared to its 5-year average forward P/E of -3.26. For a more detailed relative valuation and DCF analysis to assess GT Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.26
Current PE
-0.67
Overvalued PE
0.62
Undervalued PE
-7.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GTBP News & Events

Events Timeline

(ET)
2025-11-14
09:04:37
GT Biopharma announces Q3 net loss of $3.1M, down from $3.4M the previous year.
select
2025-10-23 (ET)
2025-10-23
09:05:35
GT Biopharma announces enrollment progress for GTB-3650 Phase 1 trial
select
2025-10-08 (ET)
2025-10-08
09:08:52
GT Biopharma Shares Enrollment Progress for GTB-3650 Phase 1 Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:13 AMNewsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six patients treated across the cohorts showing no safety or tolerability issues, indicating strong tolerability of the therapy for relapsed blood cancers.
  • Dose Advancement: The company is now advancing to Cohort 4, where patients will receive a dose of 10μg/kg/day, which is believed to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and driving further clinical trial progress.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide critical clinical data updates in the first quarter of 2026, further boosting investor confidence.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, demonstrating potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.0
01:42 AMPRnewswire
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six participants showing no safety or tolerability issues at progressively higher doses, indicating the therapy's potential in treating relapsed blood cancers.
  • Dose Advancement: The company has moved into Cohort 4, where patients will receive a dose of 10μg/kg/day, which is expected to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and improving patient prognosis.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide a more comprehensive clinical update in the first quarter of 2026.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, showcasing innovative potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
2.0
11-17Benzinga
Quantum Computing Stocks Surge Over 23%; Check Out 20 Premarket Movers

  • Quantum Computing Inc. Performance: Quantum Computing Inc. shares surged 23.5% in pre-market trading after reporting better-than-expected Q3 earnings of 1 cent per share, compared to a projected loss of 6 cents, and sales of $384,000, exceeding expectations of $116,667.

  • Other Notable Gainers: WeShop Holdings Limited saw a dramatic increase of 98.6% to $60.00, while MSP Recovery, Genius Group, and Repare Therapeutics also experienced significant gains in pre-market trading.

  • Major Losers: Taitron Components Incorporated fell 39.5% to $1.27 after announcing a quarterly loss and voluntary delisting, while Sonder Holdings Inc. declined 28.6% following a Chapter 7 bankruptcy filing.

  • Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, with notable fluctuations in share prices following recent earnings reports and corporate announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GT Biopharma Inc (GTBP) stock price today?

The current price of GTBP is 0.6298 USD — it has increased 3.62 % in the last trading day.

arrow icon

What is GT Biopharma Inc (GTBP)'s business?

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

arrow icon

What is the price predicton of GTBP Stock?

Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GT Biopharma Inc (GTBP)'s revenue for the last quarter?

GT Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is GT Biopharma Inc (GTBP)'s earnings per share (EPS) for the last quarter?

GT Biopharma Inc. EPS for the last quarter amounts to -0.83 USD, decreased -45.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for GT Biopharma Inc (GTBP)'s fundamentals?

The market is revising No Change the revenue expectations for GT Biopharma, Inc. (GTBP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.35%.
arrow icon

How many employees does GT Biopharma Inc (GTBP). have?

GT Biopharma Inc (GTBP) has 1 emplpoyees as of December 05 2025.

arrow icon

What is GT Biopharma Inc (GTBP) market cap?

Today GTBP has the market capitalization of 6.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free